Apr 21 2010
Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Imipramine Pamoate capsules, 75 mg, 100 mg, 125 mg and 150 mg strengths. Commercial shipments of the product have already commenced.
Lupin's Imipramine Pamoate capsules are the AB-rated generic equivalent of Mallinckrodt's *Tofranil-PM®. Imipramine Pamoate capsules had annual sales of approximately $39 million for the twelve months ended December 2009, based on IMS Health sales data.
Source:
Lupin Pharmaceuticals, Inc.
Georgetown study raises concerns over aspirin's role in breast cancer treatment